Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

To learn more, please visit www.reprievetrial.org.

A study presented at CROI 2025 reveals that a single-question self-efficacy measure effectively predicts ART adherence and viral load suppression among pregnant women with HIV in Malawi, offering a ...

A 15-year study by Kaiser Permanente Northern California reveals significant gaps in LTBI testing practices, highlighting the need for targeted strategies to prevent active TB cases.